Anti-atherosclerotic effects of perilla oil in rabbits fed a high-cholesterol diet

被引：4

作者：

Cha Y. ^{[1
]}

Jang J.Y. ^{[1
]}

Ban Y.-H. ^{[1
]}

Guo H. ^{[1
]}

Shin K. ^{[1
]}

Kim T.-S. ^{[2
]}

Lee S.-P. ^{[2
]}

Choi J. ^{[1
]}

An E.-S. ^{[1
]}

Seo D.-W. ^{[1
]}

Yon J.-M. ^{[1
]}

Choi E.-K. ^{[1
]}

Kim Y.-B. ^{[1
]}

机构：

[1] College of Veterinary Medicine, Chungbuk National University, 1 Chungdaero (Gaesin-dong), Cheongju, Chungbuk

[2] Anydoctor Healthcare Co., Ltd., Cheonan

来源：

Laboratory Animal Research | 2016年 / 32卷 / 3期

关键词：

atherosclerosis; fatty liver; Hypercholesterolemia; lipid peroxidation; perilla oil;

D O I：

10.5625/lar.2016.32.3.171

中图分类号：

学科分类号：

摘要：

Anti-atherosclerosis effects of perilla oil were investigated, in comparison with lovastatin, in rabbits fed a high-cholesterol diet (HCD). Hypercholesterolemia was induced in rabbits by feeding the HCD containing 0.5% cholesterol and 1% corn oil, and perilla oil (0.1 or 0.3%) was added to the diet containing 0.5% cholesterol for 10 weeks. HCD greatly increased blood total cholesterol and low-density lipoproteins, and caused thick atheromatous plaques, covering 74% of the aortic wall. Hyper-cholesterolemia also induced lipid accumulation in the liver and kidneys, leading to lipid peroxidation. Perilla oil not only attenuated hypercholesterolemia and atheroma formation, but also reduced fat accumulation and lipid peroxidation in hepatic and renal tissues. The results indicate that perilla oil prevents atherosclerosis and fatty liver by controlling lipid metabolism, and that it could be the first choice oil to improve diet-induced metabolic syndrome. © 2016, BioMed Central Ltd.

引用

页码：171 / 179

页数：8

共 45 条

[1] Huh K.B., The present status of nutrition-related diseases and its countermeasures, Kor J Nutr, 23, 3, pp. 197-207, (1990)
[2] Lee H.K., Pattern of disease incidence and nutrition in Korea, Kor J Nutr, 29, 4, pp. 381-383, (1996)
[3] Lee Y.C., Hypercholesterolemia in Korea and nutritional factors, Korean Soc Lipidol Atherosc, 1, 1, pp. 111-122, (1991)
[4] Spady D.K., Woollett L.A., Dietschy J.M., Regulation of plasma LDL-cholesterol levels by dietary cholesterol and fatty acids, Annu Rev Nutr, 13, pp. 355-381, (1993)
[5] Natio H.K., Atherogenesis: current topics on etiology and risk factors, Clin Chem, 41, 1, pp. 132-133, (1995)
[6] Bemis C.E., Gorlin R., Kemp H.G., Herman M.V., Progression of coronary artery disease. A clinical arteriographic study, Circulation, 47, 3, pp. 455-464, (1973)
[7] Kannel W.B., Castelli W.P., Gordon T., McNamara P.M., Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study, Ann Intern Med, 74, 1, pp. 1-12, (1971)
[8] Jialal I., Devaraj S., The role of oxidized low density lipoprotein in atherogenesis, J Nutr, 126, pp. 1053S-1057S, (1996)
[9] Glass C.K., Witztum J.L., Atherosclerosis. the road ahead, Cell, 104, 4, pp. 503-516, (2001)
[10] Blum A., Simsolo C., Hasin Y., 3-Hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors (statins), atherosclerosis and coronary syndromes, Atherosclerosis, 175, 1, pp. 1-5, (2004)

← 1 2 3 4 5 →